When diffuse large B-cell lymphoma secondarily involves the central nervous system while systemic disease remains active at other sites, both compartments must be addressed as part of the treatment strategy.
Secondary CNS involvement by diffuse large B-cell lymphoma, with concurrent systemic disease present at additional sites. This configuration demands a coordinated approach that reaches both the central nervous system and the systemic disease burden.
Management involves treatment directed at the systemic disease, combined with an agent specifically added to address the CNS component — the complete regimen, sequencing, and eligibility criteria are contained in the full structured protocol.
DOI: 10.1038/s41408-026-01458-2
Secondary involvement of the CNS requires treatment to target the systemic disease with the addition of high-dose methotrexate to treat the CNS.
View source ↗